IMMURON Common Stock Net 2018-2024 | IMRN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IMMURON common stock net from 2018 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

IMMURON common stock net from 2018 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.6B
Amgen (AMGN)	$164.4B
Gilead Sciences (GILD)	$137B
Vertex Pharmaceuticals (VRTX)	$120.7B
Bristol Myers Squibb (BMY)	$97.7B
CSL (CSLLY)	$84.2B
GSK (GSK)	$75.8B
Regeneron Pharmaceuticals (REGN)	$60.6B
Alnylam Pharmaceuticals (ALNY)	$42.4B
Argenex SE (ARGX)	$35B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$20.3B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$16.2B
Genmab (GMAB)	$14B
Genmab (GNMSF)	$13.8B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$12.7B
Exelixis (EXEL)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.1B
Exact Sciences (EXAS)	$9.4B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.8B